2月4日,默沙东宣布将暂停向中国市场供应佳达修HPV宫颈癌疫苗,此次供应暂停将至少持续至2025年年中,原因是中国市场对HPV疫苗需求疲弱。默沙东股价盘前下跌8%。就在不久前,默沙东的佳达修HPV疫苗多项新适应症获得国家药品监督管理局的上市批准,适用于9岁至26岁男性接种,成为中国境内首个且目前唯一获批、可适用于男性的HPV疫苗。默沙东的HPV疫苗是该公司除肿瘤药物帕博利珠单抗(Keytruda)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.